人脑胶质瘤CXCL12基因的甲基化分析研究

Objective To detect the methylation status of CXCL12 gene and the mRNA expression of CXCL12, CXCR4 and DNA methyhransferases (DNMTs) in glioma, and to analyze the methylation regulation and mechanism of CXCL12/CXCR4 signaling axis in the malignant progress of glioma. Methods The mRNA expression of CXCL12, CXCR4, DNMT1, DNMT3A and DNMT3B was detected by the semi - quantitative RT - PCR and real - time PCR in 76 gliomas and 10 normal brain tissues. The methylation status of CXCL12 in glioma was also studied by the methylation specific PCR. Results ( 1 ) The mRNA expression of CXCR4 in glioma increased with WHO grades. (2) Methylation of CXCL12 was detected in 34. 2% ( 26/76 ) of gliomas, but the methylation rate decreased with WHO grades. ( 3 ) Epigenetic inactivation of CXCL12 mainly happened in low- grade gliomas, and the CXCL12 mRNA levels were closely related to its methylation status. (4) The expression levels of these three DNMT genes were significantly higher in the CXCL12 - methylated gliomas than in the CXCL12 - unmethylated ones. Conclusion The CXCR4 gene may be a marker of aggressive biological behavior of glioma. The CXCL12 promoter hypermethylation is detected mainly in low - grade gliomas. And the methylaiton of CXCL12 gene cause the down - regulation of its mRNA levels in low - grade gliomas. The high expressions of DNMT1、DNMT3A and DNMT3B may be the potential mechanism of CXCL12 methylation.     

颅内动脉瘤破裂导致脑内血肿的诊断与治疗

目的探讨颅内动脉瘤破裂导致脑内血肿的诊断和治疗原则。方法本组男15例，女12例，年龄18～67岁，平均51岁。27例脑内血肿均经脑血管造影（DSA）或CT脑血管造影（CTA）检查确诊，其中前交通动脉瘤7例，后交通动脉瘤10例，大脑中动脉瘤9例，后交通动脉瘤合并大脑中动脉瘤1例。本研究对其临床表现、影像学特点及处理原则分别进行了分析。结果27例患者中有24例行开颅动脉瘤夹闭及血肿清除术，2例行股动脉穿刺血管内弹簧圈栓塞治疗，1例行DSA检查确诊动脉瘤后术前准备时再出血，抢救无效死亡。根据GOS分级，本组Ⅰ级3例，Ⅱ级1例，Ⅲ级3例，Ⅳ级7例，Ⅴ级13例。结论某些特殊部位的白发性脑内血肿，有可能是颅内动脉瘤破裂出血所致，需尽早行DSA或CTA检查明确诊断，治疗以手术为首选，术中夹闭动脉瘤并将血肿清除。     

自发性SAH的脑血管造影检查

目前，随着ＣＴ和ＭＲ的广泛应用，ＳＡＨ的确诊率明显升高，但因ＳＡＨ是由多种病因所致，故其临床处理的关键在于正确找出ＳＡＨ的原发病。脑血管造影检查即是临床上明确ＳＡＨ出血原因简便而确切的重要方法。近年来，随着数字减影血管造影（ＤＳＡ）技术的推广，临床医...     

脑胶质瘤患者病理分级与微血管密度的相关性研究

目的:探讨不同的脑胶质瘤病理分级与瘤内微血管密度的相关性.方法:用免疫组化的方法对38例不同病理类型的胶质瘤进行微血管密度测定,利用方差分析判断微血管密度与胶质瘤病理学分级的关系.结果:脑胶质瘤内微血管密度值的大小与肿瘤恶性程度呈正相关.结论:测定脑胶质瘤内微血管密度可以判断肿瘤的生物学行为.     

人脑胶质瘤CXCL12基因的甲基化分析研究

Objective To detect the methylation status of CXCL12 gene and the mRNA expression of CXCL12, CXCR4 and DNA methyhransferases (DNMTs) in glioma, and to analyze the methylation regulation and mechanism of CXCL12/CXCR4 signaling axis in the malignant progress of glioma. Methods The mRNA expression of CXCL12, CXCR4, DNMT1, DNMT3A and DNMT3B was detected by the semi - quantitative RT - PCR and real - time PCR in 76 gliomas and 10 normal brain tissues. The methylation status of CXCL12 in glioma was also studied by the methylation specific PCR. Results ( 1 ) The mRNA expression of CXCR4 in glioma increased with WHO grades. (2) Methylation of CXCL12 was detected in 34. 2% ( 26/76 ) of gliomas, but the methylation rate decreased with WHO grades. ( 3 ) Epigenetic inactivation of CXCL12 mainly happened in low- grade gliomas, and the CXCL12 mRNA levels were closely related to its methylation status. (4) The expression levels of these three DNMT genes were significantly higher in the CXCL12 - methylated gliomas than in the CXCL12 - unmethylated ones. Conclusion The CXCR4 gene may be a marker of aggressive biological behavior of glioma. The CXCL12 promoter hypermethylation is detected mainly in low - grade gliomas. And the methylaiton of CXCL12 gene cause the down - regulation of its mRNA levels in low - grade gliomas. The high expressions of DNMT1、DNMT3A and DNMT3B may be the potential mechanism of CXCL12 methylation.     

颅内恶性肿瘤继发三叉神经痛6例报道

颅内恶性肿瘤继发三叉神经痛临床上少见,复习我院1960年以来2000余例桥小脑角肿瘤病例,6例恶性肿瘤患者表现为三叉神经痛,现报告如下。     

选择性脊神经后根切断术治疗痉挛性脑性瘫痪(附11例报告)

选择性脊神经后根切断术(ＳｅｌｅｃｔｉｖｅＰｏｓｔｅｒｉｏｒＲｈｉｌｏｔｏｍｙ,ＳＰＲ)是功能性神经外科治疗痉挛性脑瘫的具有可靠疗效的外科治疗方法之一。我院自1994年5月～1996年6月采用该手术方法治疗11例,均取得了良好疗效,手术要点及体会报告如下:临床资料本组11例,     

脑积水的外科治疗及其并发症

目的探讨脑积水的外科治疗方法及术后并发症的处理。方法回顾性分析180例脑积水病人的相关资料。结果共有152例行手术分流,1次分流成功101例(66%)。术后出现并发症51例(34%)。分流的并发症包括分流系统梗阻、感染、过度分流、癫和腹腔脏器损伤等。按照Salmon提出的关于脑积水分流术后手术效果的6级评判法将随诊结果分类。结论脑积水的外科治疗以临床上较为成熟的方法为主,要做到因病施治,治疗过程中要把握各个环节,防止并发症的发生。     

TaqMan低密度表达芯片检测DNA损伤修复基因在原发胶质瘤中的表达研究

目的运用低密度表达谱芯片检测人脑原发胶质瘤组织中DNA损伤修复基因的表达情况,进一步分析其表达变化的意义。方法使用TaqMan低密度表达芯片技术检测27个DNA损伤修复基因在40例不同级别原发胶质瘤组织和10例正常脑组织中的表达情况,并通过统计学分析其在不同级别胶质瘤和正常脑组织中的表达差异。结果与正常脑组织相比较,有13个DNA损伤修复基因在Ⅱ、Ⅲ、Ⅳ级胶质瘤中均表达下调,包括ERCC1、ERCC2、ERCC3、ERCCA、MGMT、MLH1、MLH3、NTHL1、OGG1、RAD50、SMUG1、XRCC4、XRCC5(P<0.05)。MSH2、MSH6、NUDT1和XRCC3只在Ⅱ级和Ⅲ级胶质瘤中表达下凋;MRE11A和MUS81只在Ⅲ级和Ⅳ级胶质瘤中表达下调。PMS2、RAD52和XRCC1只在Ⅲ级胶质瘤中表达下调,而UNG只在Ⅱ级中表达下调。结论TaqMan低密度表达芯片为多个基因的同时定量表达提供了一种准确、快速、有效的多变量检测技术,可用于发现新的肿瘤相关基因。大量的DNA损伤修复基因的表达下调,与胶质瘤的发生密切相关。     

人脑胶质瘤逃逸免疫监视机制的研究

目的 探讨Thl／Th2类细胞因子基因在人脑胶质瘤中的表达情况，以及它们在脑胶质瘤发生及发展中的作用。方法 以IL-2、IFNγ代表Thl类细胞因子，IL-4、IL-6及IL-10代表Th2类细胞因子，采用逆转录聚合酶链反应方法(RT-PCR)检测Thl／Th2类细胞因子基因在脑胶质瘤细胞、肿瘤浸润淋巴细胞及细胞株中的表达情况。结果 人脑胶质瘤细胞、肿瘤浸润淋巴细胞及脑胶质瘤细胞株均呈现明显的Th2类细胞因子基因优势表达，而正常人脑组织中则无这种表达趋势。结论 Th2类细胞因子在人脑胶质瘤中的优势表达可能是导致脑胶质瘤患者细胞免疫功能低下的原因之一，有可能在脑胶质瘤的发生及发展中起一定作用。